Fareon Open Label Device Clinical Trial
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16+
SponsorIcahn School of Medicine at Mount Sinai
About this trial
The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME/CFS), and other neurodegenerative diagnoses including but not limited to Alzheimer's disease and to collect data on safety and efficacy to inform the design of larger clinical studies.
Eligibility criteria
Qualifiers
Any sex/gender
16 years of age or older
English Speaking
Experiencing symptoms of at least self-reported mild cognitive impairment associated with a confirmed diagnosis of a condition such as Long COVID, Traumatic Brain Injury, other Acquired Brain Injuries, and other neurodegenerative diagnoses including but not limited to Alzheimer's disease
Disqualifiers
Enrollment in another interventional clinical trial in the last 90 days or during the study period
Change in anti-depressant or other psychoactive medication or dose in the last 90 days
Cranially implanted devices or metal
Pacemaker
Trial design
Treatments tested in this trial
- Fareon device
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov